NCT06816810
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Sep 2027 Show 6 more changesShow less
- Eligibility criteria expanded, about 3 words
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Start date changed from estimate of Mar 2025 to Jun 9, 2025
- Secondary endpoints: details revised at 7 of 7 entries
- Site contact updated
- Publications: details revised at 27 of 28 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Throughout enrollment (4 weeks of screening) to the end of treatment at 48 weeks and 4-week safety follow-up.
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical Motor Progression Using MDS-UPDRS Part III
Timeframe: Throughout enrollment to the end of treatment at 48 weeks. MDS-UPDRS Part III will be evaluated at baseline, 24 weeks and 48 weeks.
Secondary (7)
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using CGI-C Scale
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using CGI-S Scale
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using PGI-S Scale
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using PGI-C Scale
Change in Quality of Life (QoL) as assessed by the PDQ-8
Show 2 moreShow less
Efficacy of Hydroxychloroquine (HCQ) Using Change in Modified Hoehn and Yahr Scale
Efficacy of Hydroxychloroquine (HCQ) in Slowing Clinical Disease Progression as Assessed by the MDS-UPDRS
Arms and interventions
Hydroxychloroquine Treatment for Early Parkinson's Disease (HCQ-PD)Experimental
This is an open-label study where 40 participants with early-treated Parkinson's Disease will be receive 200mg of Hydroxychloroquine, orally, twice daily for 48 weeks.
Drugs: Hydroxychloroquine (HCQ)
Sites
1 site in 1 country
- The Ottawa HospitalOttawa, Ontario, Canada